Overview

* Ocugen ( OCGN ) Q2 revenue beats analyst expectations, reaching $1.37 mln

* Company initiates dosing in OCU410ST Phase 2/3 GARDian3 trial

* Ocugen ( OCGN ) announces reverse merger with OrthoCellix to focus on regenerative therapies

Outlook

* Ocugen ( OCGN ) aims for 2026 BLA filings for OCU400 and OCU410ST

* Ocugen ( OCGN ) progressing with OCU410ST Phase 2/3 trial for Stargardt disease

* Proposed merger with OrthoCellix to focus on regenerative cell therapies

Result Drivers

* CLINICAL TRIAL ADVANCEMENT - Ocugen ( OCGN ) is actively dosing patients in late-stage trials for OCU400 and OCU410ST

* STRATEGIC PARTNERSHIPS - Signed binding term sheet for exclusive Korean rights to OCU400, with potential payments up to $11 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.37 $350,000

Revenue mln (4

Analysts

)

Q2 EPS -$0.05

Q2 Net -$14.74

Income mln

Q2 $15.17

Operatin mln

g

Expenses

Q2 -$13.80

Profit mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Ocugen Inc ( OCGN ) is $7.00, about 85.3% above its July 31 closing price of $1.03

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)